| Name | Title | Contact Details |
|---|
The mission of Nevada Legal Services is to strengthen the community by ensuring fairness and providing equal access to justice for low income Nevadans. NLS receives the Legal Services Corporation funding for the state of Nevada. We represent qualified individuals in subsidized housing applications, terminations, and eviction, unemployment insurance benefits, Social Security disability appeals, welfare benefits, tax controveries, and limited immigration and family law.
Hancock and Moore Fine Furniture
With 20+ years of collective experience, OeP helps brands capitalize on Amazons growth, using data-driven strategies executed by experts, enabled by technology, and aligned with Amazons dynamic platform and KPIs.
NuVision Auto Glass is one of the fastest growing auto glass companies in the US. Over 100K happy drivers. Rated 4.5⭐ on Google Serving Arizona, Florida and South Carolina
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.